moderate-
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. physician-diagnosed of moderate-severe persistent allergic rhinitis for at least 1 year duration with TNSS (Total nasal symptoms score) equal or greater than 6 2. Recent skin prick test result within 1 year which shown positive for at least 1 aeroallergen
Exclusion criteria
Exclusion criteria: 1. Patients who were pregnant or in lactating period 2. Recent use of oral or topical decongestant within 7 days, intranasal steroid within 4 weeks, systemic corticosteroid within 8 weeks, H1-antihistamine or anti-leukotriene within 2 weeks and systemic corticosteroid within 8 weeks 3. Concurrent diseases such as asthma, urticaria and atopic dermatitis 4. Patients who were currently or previously treated with immunotherapy 5. Patients who were diagnosed with upper respiratory tract infection within the previous 14 days 6. Patients with rhinosinusitis, nasal polyps or significant deviated nasal septum. 7. Patients with a history of asthma, chronic lung diseases, cardiovascular, hepatic, or renal diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effectiveness of daily versus as-needed use of fluticasone furoate nasal spray 6 weeks Total nasal symptom score | — |
Secondary
| Measure | Time frame |
|---|---|
| Accumulation dose of daily versus as-needed fluticasone furoate nasal spray 6 weeks Accumulative dose of fluticasone furoate,Effectiveness of fluticasone furoate nasal spray within each group 6 weeks Total nasal symptom score,Nasal peak inspiratory flow rate between of daily versus as-needed fluticasone furoate group 6 weeks NPIF,Quality of life of daily of daily versus as-needed fluticasone furoate group 6 weeks RCQ-36 score | — |
Contacts
Department of medicine Siriraj hospital, Mahidol university